Autosomal dominant neovascular inflammatory vitreoretinopathy is a rare, inherited eye condition that affects the retina and the clear gel of the eye. People with Autosomal dominant neovascular inflammatory vitreoretinopathy often notice floaters, blurred vision, and trouble seeing at night that slowly worsen over years. It is lifelong, and signs often begin in adolescence or early adulthood but can vary by family. Treatment focuses on reducing eye inflammation and abnormal blood vessel growth with eye drops, injections, or surgery, and vision aids can help daily life. The outlook depends on severity and timely care, and many living with Autosomal dominant neovascular inflammatory vitreoretinopathy benefit from regular follow-up with a retina specialist.
Overview
Autosomal dominant neovascular inflammatory vitreoretinopathySymptoms
Autosomal dominant neovascular inflammatory vitreoretinopathy causes worsening vision problems. People may notice floaters, light flashes, blurry or distorted sight, poor night vision, and narrowing side vision; episodes of eye redness or pain can occur. Without treatment, vision loss can progress.
Outlook and prognosis
Many living with autosomal dominant neovascular inflammatory vitreoretinopathy face slowly progressive vision changes, often starting with night blindness and peripheral vision loss. Regular retina care, anti‑inflammatory and anti‑VEGF treatments, and timely surgery can preserve functional sight. Family screening helps anticipate needs early.
Causes and risk factors
Autosomal dominant neovascular inflammatory vitreoretinopathy is caused by CAPN5 gene mutations, often inherited from an affected parent; new mutations can occur. Risk is highest with a family history. No confirmed lifestyle or environmental causes; general inflammatory triggers may modify severity.
Genetic influences
Genetics play a central role in autosomal dominant neovascular inflammatory vitreoretinopathy, with most cases caused by inherited variants, often in the CAPN5 gene. A single altered copy can be enough to cause disease. Family history strongly guides risk, testing, and counseling.
Diagnosis
Doctors suspect autosomal dominant neovascular inflammatory vitreoretinopathy based on family history and clinical eye findings. Retinal imaging rules out mimics, while genetic tests confirm the diagnosis of autosomal dominant neovascular inflammatory vitreoretinopathy. A retina specialist coordinates genetic testing and counseling.
Treatment and drugs
Treatment for autosomal dominant neovascular inflammatory vitreoretinopathy focuses on calming eye inflammation, preventing leaky or new blood vessels, and preserving vision. Care often includes steroid eye drops or injections, immune‑modulating pills, and anti‑VEGF injections; laser or retinal surgery may help complications. Regular retinal imaging guides timely adjustments.
Symptoms
Day to day, it can start with small shifts in how you see—blurred text, specks drifting across your view, or glare that seems harsher than before. The changes are often subtle at first, blending into daily life until they become more noticeable. People often ask about early features of Autosomal dominant neovascular inflammatory vitreoretinopathy; common early signs include floaters and blurred vision from inflammation in the eye’s gel. As it evolves, other features can appear, such as light sensitivity, wavy lines from central retinal swelling, or trouble with side and night vision.
Things can look fuzzy or out of focus, especially when reading or looking across a room. In this condition, inflammation or swelling in the retina can blur fine details. Sharpness may come and go at first.
You may see moving gray specks or cobwebs drifting across your view. These come from clumps in the eye’s gel during inflammation in Autosomal dominant neovascular inflammatory vitreoretinopathy. A sudden increase can make the view hazy or patchy.
Bright sunlight or screens can feel harsh or glaring. This often flares when the eye is inflamed and can ease as inflammation settles.
Straight lines can appear bent, and faces may look stretched. This can happen when fluid builds up in the center of the retina, where sharp vision happens.
How people usually first notice Autosomal dominant neovascular inflammatory vitreoretinopathy?
People often first notice autosomal dominant neovascular inflammatory vitreoretinopathy when night vision starts to slip or peripheral vision feels “narrowed,” sometimes described as bumping into things at the edges or struggling in dim light. In families with a known history, the first signs of autosomal dominant neovascular inflammatory vitreoretinopathy may be picked up during routine eye exams, where an ophthalmologist sees inflammation, abnormal new blood vessels, or early changes in the retina even before symptoms are obvious. As the condition progresses, some develop floaters, blurred vision, or flashes of light, which prompt a detailed retinal evaluation to confirm how autosomal dominant neovascular inflammatory vitreoretinopathy is first noticed.
Types of Autosomal dominant neovascular inflammatory vitreoretinopathy
Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare inherited eye condition that typically worsens over time and affects both eyes. People with ADNIV share a core pattern—eye inflammation, abnormal blood vessel growth, and scarring—but there are recognized clinical variants that differ by when problems begin and how fast vision changes. Doctors sometimes classify these as early- versus later-onset patterns tied to mutations in the same gene, with overlapping features. Not everyone will experience every type.
Early-onset variant
Symptoms often start in late childhood to early adulthood with floaters, light sensitivity, and episodic eye inflammation. Over time, scar tissue and abnormal retinal blood vessels can lead to peripheral vision loss, then central vision changes.
Classic adult-onset
Many notice problems in their 20s to 40s, with gradual inflammation followed by abnormal vessel growth and vitreous haze. Vision typically declines in steps during flares, and macular swelling may come and go.
Neovascular-predominant
Abnormal retinal or iris blood vessels stand out early, sometimes with bleeding in the eye. Inflammation is present but milder at first, and glaucoma risk can rise as new vessels block drainage.
Inflammation-predominant
Recurrent uveitis-like flares dominate the picture with redness, pain, and blurred vision. Scarring and traction can develop later, pulling on the retina and increasing risk for retinal detachment.
Tractional/scarring phase
Scar tissue on the retinal surface and in the vitreous becomes the main driver of symptoms. People may notice more distortion and field loss as the retina is tugged, even if inflammation feels quieter.
Advanced end-stage
Severe scarring and repeated bleeding can lead to extensive vision loss in both eyes. Low-vision rehabilitation and supportive tools become central to daily functioning. Keeping track of types of autosomal dominant neovascular inflammatory vitreoretinopathy can help set expectations for care.
What genetics can tell you about symptoms
Some people with CAPN5 gene variants develop early floaters, light sensitivity, and blurry vision that can flare like bouts of eye inflammation. Certain changes drive abnormal retinal blood vessel growth, leading to bleeding, scar tissue, retinal detachment, and progressive vision loss.
Causes and risk factors
A change in the CAPN5 gene causes this condition and is usually inherited in an autosomal dominant way. Doctors distinguish between risk factors you can change and those you can’t. The strongest risk is having a parent with the CAPN5 change, which gives each child a 50% chance of inheriting it. Eye injuries, smoking, and uncontrolled inflammation may worsen eye damage and abnormal vessel growth, but they do not cause the disease. Share your family history with your eye doctor so they can watch for early symptoms of autosomal dominant neovascular inflammatory vitreoretinopathy.
Environmental and biological risk factors
When planning a family, it’s natural to wonder what could raise the chance of a child being born with autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV). That said, biology and environment work hand in hand. Most influences here occur before birth and relate to how reproductive cells age or are exposed. Only a few are well established; others are uncommon or unproven.
Conception at an older father’s age is associated with a higher chance of new gene changes during sperm formation. This can slightly raise the likelihood that a child is born with ADNIV. The effect tends to increase gradually with age.
Exposure of a parent’s reproductive organs to high-dose ionizing radiation before conception can increase DNA damage and the chance of new changes. While not specific to this condition, such extreme exposures are recognized mutagens. These situations are uncommon and usually relate to medical therapy or major occupational incidents.
No everyday environmental exposures have been proven to raise the risk of this condition. Research to date has not identified specific pollutants, infections, or household factors that increase likelihood. Ongoing studies continue to watch for any clear links.
Genetic risk factors
Genetic risk for Autosomal dominant neovascular inflammatory vitreoretinopathy centers on rare, harmful changes in the CAPN5 gene that are passed down in families. Some risk factors are inherited through our genes. Because this condition follows an autosomal dominant pattern, each child of an affected parent has a 50% chance of inheriting the gene change. Early symptoms of Autosomal dominant neovascular inflammatory vitreoretinopathy can appear at different ages, even among relatives, reflecting variable expressivity and age-related penetrance.
CAPN5 gene variants: Pathogenic changes in the CAPN5 gene drive Autosomal dominant neovascular inflammatory vitreoretinopathy. These changes make the calpain-5 protein overactive, which can set off inflammation, abnormal vessel growth, and damage in the retina.
Autosomal dominant inheritance: If a parent carries a disease-causing CAPN5 change, each child has a 50% chance to inherit it. This risk is the same for all pregnancies, regardless of sex. Children who do not inherit the change are not at increased genetic risk.
Family history: Having a biological parent or close relative with a confirmed CAPN5 variant strongly increases risk. First-degree relatives are the most likely to carry the same change. Several generations can be affected in larger families.
Age-related penetrance: Most people who inherit a disease-causing CAPN5 variant eventually develop features of Autosomal dominant neovascular inflammatory vitreoretinopathy, but timing can range from adolescence to later adulthood. Severity and specific features can differ even within the same family. This variability can affect when diagnosis is made.
De novo variants: Sometimes the CAPN5 change arises for the first time in a child with no prior family history of Autosomal dominant neovascular inflammatory vitreoretinopathy. That individual still has a 50% chance to pass it to each future child. Parents without the variant are typically not at increased risk.
Parental mosaicism (rare): Very rarely, a parent carries the CAPN5 change in only some egg or sperm cells and may have no symptoms. This can slightly raise the chance of having another affected child even when standard blood testing in the parent is negative.
Variant differences: Different CAPN5 changes can influence how early symptoms start and how quickly the condition progresses. This helps explain why some relatives are affected earlier or more severely than others. These variant-specific patterns are becoming clearer as more families are studied.
Lifestyle risk factors
Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an inherited eye condition; lifestyle habits do not cause it, but they can influence how inflammation, neovascular growth, and complications unfold. People often ask about lifestyle risk factors for Autosomal dominant neovascular inflammatory vitreoretinopathy; the focus is on choices that can ease inflammation, reduce bleeding risk, and support treatment. The points below connect daily habits to concrete effects on ocular inflammation, neovascularization, macular edema, and surgical outcomes. Work with your eye specialist to tailor changes to your stage of disease and treatment plan.
Tobacco and nicotine exposure can amplify ocular inflammation and pro-angiogenic signaling, which may worsen neovascularization in ADNIV. Smokers have higher risks of vitreous hemorrhage and poorer healing after eye procedures.
Strenuous, jarring exercise or heavy lifting that triggers Valsalva can precipitate vitreous hemorrhage in eyes with fragile neovascular vessels. Favor low-impact cardio and strength work that avoids straining to maintain fitness without stressing the retina.
Meals rich in omega-3s, colorful produce, legumes, and nuts may help dampen systemic inflammation that can fuel uveitis and macular edema. Limiting ultra-processed and high-glycemic foods may reduce inflammatory swings that aggravate ocular disease.
High-salt intake can raise blood pressure, which can increase retinal vascular leakage and bleeding risk in ADNIV. Moderating sodium supports steadier ocular perfusion and may lessen edema burden.
Risk prevention
Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) can’t be prevented outright, but you can lower the chance of flare-ups and vision loss. Prevention is about lowering risk, not eliminating it completely. The goal is to catch changes early and treat promptly so inflammation and abnormal blood vessels don’t cause lasting damage. Family awareness and regular specialist care make the biggest difference over time.
See an eye specialist for dilated exams every 6–12 months, or sooner if symptoms change. This helps catch early symptoms of autosomal dominant neovascular inflammatory vitreoretinopathy before they threaten vision.
New floaters, flashes, eye pain, or a sudden blur deserve urgent attention. Quick care can calm inflammation and prevent scarring in ADNIV.
Ongoing follow-up with a uveitis/retina specialist helps tailor treatment as the disease shifts. Timely therapy for inflammation and new vessels lowers the risk of bleeding and retinal damage.
Take prescribed drops, tablets, or injections on schedule, and keep laser or clinic appointments. Consistent treatment reduces flare frequency and protects vision in ADNIV.
Transmission
Autosomal dominant neovascular inflammatory vitreoretinopathy is not contagious; it cannot be caught from contact, air, or bodily fluids. It follows an autosomal dominant pattern of inheritance, meaning if a parent has the condition, each child has a 50% (1 in 2) chance of inheriting the gene change.
It can also arise from a new gene change that happens for the first time, though this is less common. Severity and the age symptoms start can vary widely, even among relatives who inherit the same change, so families often consider genetic counseling to understand how Autosomal dominant neovascular inflammatory vitreoretinopathy is inherited in their family.
When to test your genes
Consider genetic testing if you or close relatives have early vision problems (floaters, night blindness, peripheral vision loss) or a family history of autoimmune-like eye inflammation and retinal blood vessel growth. Testing is also reasonable before family planning or when planning eye surgery to guide surveillance and treatment. Ask for a retina-focused panel including CAPN5.
Diagnosis
You might notice small changes in daily routines, like more floaters, glare, or trouble with night driving, that bring you to an eye exam. Because Autosomal dominant neovascular inflammatory vitreoretinopathy is rare and inherited, diagnosis often blends what the eye doctor sees with a few focused tests. Family history is often a key part of the diagnostic conversation. A genetic diagnosis of Autosomal dominant neovascular inflammatory vitreoretinopathy usually combines these findings with DNA testing for the known gene changes.
The eye doctor looks for inflammation in the gel of the eye, fragile new vessels, and scarring on the retina. Seeing these patterns in both eyes over time helps distinguish this condition from other causes of uveitis.
A small amount of dye is injected into a vein, then photos map blood flow in the retina. This can show leaky or new blood vessels and areas of active inflammation.
This painless light-based scan takes cross‑section pictures of the retina. It can reveal swelling, thinning, or membranes that pull on the retina as the disease progresses.
This test measures how well the retina’s cells respond to light. In this condition, ERG often shows reduced signals that reflect ongoing inflammation and degeneration.
Stages of Autosomal dominant neovascular inflammatory vitreoretinopathy
Vision changes in this condition usually unfold over many years, often starting subtly and becoming more noticeable with time. Early symptoms of Autosomal dominant neovascular inflammatory vitreoretinopathy can include blurry or fluctuating vision, light sensitivity, or trouble seeing clearly in dim settings. Early and accurate diagnosis helps you plan ahead with confidence.
Stage 1
Inflammation: Mild eye inflammation causes floaters or hazy vision that may come and go. On exam, doctors see tiny inflammatory cells in the gel of the eye.
Stage 2
Macular swelling: Fluid builds in the central retina (the macula), making reading or detailed work harder. Autosomal dominant neovascular inflammatory vitreoretinopathy at this stage often shows cyst-like pockets on scans.
Stage 3
Scar tissue: Fine scar tissue forms on the retina, which can wrinkle or pull on it. People may notice distortion, wavy lines, or a drop in sharpness.
Stage 4
New vessels: Fragile new blood vessels grow inside the eye and can bleed, causing sudden floaters or darker patches in vision. Doctors may also see abnormal vessel growth and areas starved of oxygen on imaging.
Stage 5
Late degeneration: The retina progressively loses function, leading to significant vision loss and reduced night and side vision. In advanced Autosomal dominant neovascular inflammatory vitreoretinopathy, electrical testing of the retina shows very weak responses.
Outlook and prognosis
Daily routines often adapt as vision changes come and go with Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV). Many people first notice trouble with night driving or reading fine print, then episodes of eye inflammation, floaters, or shifts in central or side vision. The outlook is not the same for everyone, but gradual vision loss can progress over years as scarring, abnormal blood vessels, and complications like cataracts or glaucoma develop. Doctors call this the prognosis—a medical word for likely outcomes.
Looking at the long-term picture can be helpful. Without consistent care, many living with ADNIV develop significant visual impairment in mid to later adulthood; some reach legal blindness in one or both eyes. Life expectancy is typically normal because ADNIV affects the eyes, not other organs, but the condition can carry a high risk of disability from vision loss. Early care can make a real difference, especially when flare-ups are treated promptly, pressure in the eye is controlled, and complications are addressed before they cause permanent damage. Not everyone with the same gene change will have the same outlook, and even within families, the pace of change can vary.
Here’s what research and experience suggest about the future. With ongoing care, many people maintain useful vision for years, particularly when treatment starts early and follow-up is steady. Treatments can’t yet cure ADNIV, but they can slow inflammation, limit abnormal vessel growth, and manage early symptoms of Autosomal dominant neovascular inflammatory vitreoretinopathy that interfere with daily tasks. Talk with your doctor about what your personal outlook might look like, including how your specific stage, family history, and response to treatment shape next steps.
Long-term effects
Autosomal dominant neovascular inflammatory vitreoretinopathy is a lifelong inherited eye condition that tends to progress over years. Long-term effects vary widely, and even relatives with the same family condition can have different paths. Over time, the eyes develop ongoing inflammation, scarring, and abnormal blood vessel growth that together threaten central and peripheral vision. Discussions of early signs of Autosomal dominant neovascular inflammatory vitreoretinopathy often contrast with the long-term picture of progressive scarring and vascular changes.
Central and side vision often decline slowly at first, then more noticeably as scarring and swelling build. Many eventually develop severe vision loss in one or both eyes.
Ongoing or repeat bouts of uveitis lead to light sensitivity and haze. This inflammation drives scarring that alters the clear gel and delicate layers inside the eye.
Cloudy strands and membranes form in the eye’s gel over time. These changes can cause persistent floaters and reduce clarity of vision.
New, fragile blood vessels grow where they should not. They can leak or bleed, adding to swelling and scar tissue that distort the retina.
How is it to live with Autosomal dominant neovascular inflammatory vitreoretinopathy?
Living with autosomal dominant neovascular inflammatory vitreoretinopathy often means adapting to vision that can change over time—periods of blurriness, floaters, light sensitivity, or distorted images—alongside regular eye exams, treatments like eye drops or injections, and sometimes surgery to preserve sight. Daily life may involve brighter task lighting, high-contrast text, larger-print or audio tools, and planning transportation when driving becomes unsafe, while managing the emotional load of an inherited condition that other family members may share. For many, support from loved ones, low-vision specialists, and genetic counseling helps with practical decisions and family planning. People around you may need to adjust routines—offering rides, reading small print, or being patient with fluctuating visual days—so that independence and connection both stay strong.
Treatment and drugs
Treatment for autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) focuses on calming eye inflammation, controlling abnormal blood vessel growth, and preserving vision for as long as possible. Many people start with anti-inflammatory eye drops or steroid injections around or into the eye; if swelling or inflammation is more severe or recurrent, doctors may add oral steroids or immunomodulating medicines to reduce the immune attack over time. To address the “neovascular” (new, fragile vessels) part of ADNIV, specialists often use anti-VEGF injections to shrink abnormal vessels and laser therapy to seal leaks and prevent bleeding; sometimes both are used together. When complications appear—such as cataracts, persistent vitreous floaters, or traction on the retina—eye surgery (including cataract extraction or vitrectomy) may help stabilize vision and improve clarity. Because ADNIV changes over years, regular follow-up with a retina specialist is key; Treatment plans often combine several approaches.
Non-drug treatment
Living with autosomal dominant neovascular inflammatory vitreoretinopathy can affect reading, driving, and night vision, sometimes in waves as the eye flares and quiets. Alongside medicines, non-drug therapies can help protect sight and support daily activities. These options focus on calming problem areas in the retina, controlling eye pressure, and making the most of the vision you have. Plans are tailored to each eye and can change as the condition evolves.
Targeted laser seals leaky or fragile retinal vessels to reduce bleeding and swelling. It can slow abnormal vessel growth and lower the risk of vision-threatening complications. Treatments may be repeated over time as the retina changes.
Surgery removes the cloudy gel and inflammatory debris that block light and cause floaters. It can relieve pulling on the retina, reduce inflammation triggers, and allow precise laser treatment during the same procedure.
Clouded lenses are common and can dim or blur vision in this condition. Replacing the lens can restore clarity, though overall vision still depends on the retina’s health.
When eye pressure stays high despite drops, surgeries like trabeculectomy or drainage implants can help. Lowering pressure protects the optic nerve and may preserve remaining vision.
Your genes may have an impact on how drugs work for you
Some medicines for autosomal dominant neovascular inflammatory vitreoretinopathy work differently depending on gene changes that affect inflammation, blood vessel growth, or drug processing. Genetic testing can sometimes guide dosing or choice of therapy, aiming for better response and fewer side effects.
Pharmacological treatments
Medicines for Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) aim to quiet eye inflammation, control abnormal blood vessel growth, reduce swelling, and protect vision over time. Not everyone responds to the same medication in the same way. Because early symptoms of Autosomal dominant neovascular inflammatory vitreoretinopathy can be subtle, treatment is often tailored and adjusted as the condition evolves. Your eye team will balance benefits and side effects, and may combine drugs to reach stable control.
Prednisone by mouth and prednisolone or dexamethasone eye drops calm active eye inflammation. Periocular or intraocular steroid injections may be used when flares are frequent or severe. Long-term use is monitored to limit pressure rise and cataract.
Methotrexate, mycophenolate mofetil, or azathioprine help reduce steroid need and maintain control. These medicines act on the immune system more broadly to prevent repeated flares. Regular blood testing is needed to track safety.
Adalimumab or infliximab may be used if inflammation persists despite other drugs. These targeted medicines can help quell difficult uveitis and protect the retina. Screening for infections is required before and during treatment.
Bevacizumab, ranibizumab, or aflibercept injections treat abnormal retinal blood vessels and leakage. They can reduce bleeding and swelling that threaten central vision. Injections are usually repeated on a schedule based on response.
Genetic influences
In this condition, the gene change follows an autosomal dominant pattern—meaning each child of an affected parent has a 50% chance of inheriting it. Autosomal dominant neovascular inflammatory vitreoretinopathy is most often linked to changes in a gene called CAPN5, which helps control inflammation and blood vessel growth in the retina. Because it’s dominant, people of any sex can be affected, and it tends to appear across multiple generations within the same family. Even with the same gene change, people can have different ages of onset and severity, so some relatives develop problems earlier while others notice issues later in life. Many who inherit a CAPN5 variant will develop features over time, but how quickly the condition progresses can vary widely. Genetic testing for autosomal dominant neovascular inflammatory vitreoretinopathy can identify the CAPN5 change in many families and help confirm the diagnosis. Test results can’t predict every detail of the future, yet they clarify risk for siblings and children and guide eye-care planning and monitoring.
Is Autosomal dominant neovascular inflammatory vitreoretinopathy genetic?
Genetics play a central role in autosomal dominant neovascular inflammatory vitreoretinopathy, with most cases caused by inherited variants, often in the CAPN5 gene. A single altered copy can be enough to cause disease. Family history strongly guides risk, testing, and counseling.
Pharmacogenetics—how genetics influence drug effects
Because autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is driven by an inherited gene change, your diagnosis is genetic, but that result rarely dictates the exact medicine you’ll receive today. Care usually relies on steroids, anti‑VEGF eye injections, and immune‑modulating drugs chosen based on how active the inflammation and abnormal vessel growth are. Not every difference in response is genetic, but pharmacogenetic information can sometimes guide safer dosing for specific medicines used in autosomal dominant neovascular inflammatory vitreoretinopathy. For example, before starting azathioprine, many doctors check activity of enzymes called TPMT or NUDT15 to lower the risk of severe low blood counts. If tacrolimus is part of treatment, a CYP3A5 result can help set the starting dose and reduce trial‑and‑error. By contrast, there is no well‑supported gene test yet to pick among anti‑VEGF agents or to predict who will respond best to steroids in autosomal dominant neovascular inflammatory vitreoretinopathy, so decisions still depend mostly on your eye findings and overall health.
Interactions with other conditions
Living with Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) alongside other health issues can change how symptoms show up and how well treatments work. Doctors call it a “comorbidity” when two conditions occur together. Autoimmune or inflammatory diseases in the body may stir up eye inflammation, and flare-ups elsewhere can make ADNIV-related uveitis and swelling harder to control. Common conditions like diabetes and high blood pressure can add to retinal bleeding or fluid buildup, sometimes making neovascular changes more severe and blurring the picture when judging early symptoms of Autosomal dominant neovascular inflammatory vitreoretinopathy. If someone also has glaucoma—or is sensitive to steroid eye drops—managing ADNIV may require extra care because steroids used to calm inflammation can raise eye pressure. People using immune-suppressing medicines for ADNIV have a higher infection risk, so vaccination plans and prompt checks for fever or new illness become especially important when other diseases are in the mix.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden changes in vision—floaters drifting like dust, a hazy film over the view, or night glare that turns driving into guesswork. Families sometimes noticed that these problems appeared across generations, starting in young adulthood and slowly progressing. Oral histories preserved stories of relatives who needed frequent eye exams or procedures, long before anyone could name what was happening inside the eye.
From early theories to modern research, the story of autosomal dominant neovascular inflammatory vitreoretinopathy, or ADNIV, traces how doctors learned to connect these signs into one condition. First described in the medical literature as a cluster of inherited inflammatory eye problems within large Midwestern families, it was initially understood through careful observation—repeated bouts of eye inflammation, abnormal blood vessel growth, and scar-like changes at the back of the eye. Over time, descriptions became more precise as photographs of the retina, angiography, and later optical coherence tomography showed a pattern that matched the clinical course families had reported for decades.
In recent decades, awareness has grown as genetic studies clarified the “autosomal dominant” inheritance pattern: a 50% chance for each child to inherit the condition when one parent is affected. Researchers linked ADNIV to changes in a gene involved in how the immune system signals inside the eye, helping explain why inflammation, new vessel growth, and later-stage scarring tend to unfold in a predictable sequence. This also clarified why early symptoms of ADNIV can look like more common eye issues at first, then evolve into a recognizable syndrome.
Medical classifications changed as doctors realized ADNIV is not simply one form of uveitis or one type of inherited retinal disease. Instead, it blends elements of both—longstanding inflammation, abnormal vessel growth (neovascularization), and degeneration of the light-sensing layer. As specialists compared notes across centers in the United States and Europe, they recognized shared timelines: often mild inflammation and floaters first, then periods of worsening with membrane formation, and eventually complications that can lower vision if untreated.
Not every early description was complete, yet together they built the foundation of today’s knowledge. Families who took part in long-term studies made it possible to map the condition’s stages and refine care. Modern imaging, better anti-inflammatory and anti-angiogenic treatments, and genetic testing have moved ADNIV from a confusing set of symptoms to a defined diagnosis. Knowing the condition’s history helps explain why early, regular eye care and family counseling now sit at the center of management.